<DOC>
	<DOC>NCT02231710</DOC>
	<brief_summary>The purpose of this study is to determine a safe dose of BPX-501 gene modified T cells infused after a haplo-identical stem cell transplant to facilitate engraftment and the safety of AP1903 on day 7 to prevent GVHD.</brief_summary>
	<brief_title>Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases</brief_title>
	<detailed_description>This is a single arm dose finding study evaluating the safety and efficacy of a BPX 501 infusion (T cells genetically modified with the inducible Caspase 9 suicide gene) of 3x10E6 to 1X10E7 cells/kg followed by an AP1903 infusion on day 7 after a partially mismatched, related, T cell-depleted hematopoietic cell transplantation (HCT) in patients with non-malignant diseases. The purpose of this clinical trial is to determine the dose of BPX 501 T cell infusion with subsequent planned infusion of AP1903 which can facilitate engraftment and prevent the occurrence of GVHD.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Pancytopenia</mesh_term>
	<mesh_term>Hemoglobinopathies</mesh_term>
	<mesh_term>Lymphohistiocytosis, Hemophagocytic</mesh_term>
	<mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
	<criteria>1. Patient must meet eligibility criteria for allogeneic transplantation 2. Males or females 3. Age &lt; 55 years old and &gt; 4 months 4. Diagnosis of a nonmalignant disorder considered treatable by HCT. 5. Lack of suitable conventional donor 1. Serious organ dysfunction 2. Pregnant or breastfeeding 3. Evidence of HIV infection 4. Bovine product allergy 5. Patients with an active infectious disease</criteria>
	<gender>All</gender>
	<minimum_age>4 Months</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Severe Combined Immune Deficiency</keyword>
	<keyword>Congenital T-cell Defect</keyword>
	<keyword>Congenital T-cell Deficiency</keyword>
	<keyword>Chronic Granulomatous Disease</keyword>
	<keyword>Shwachman Diamond Syndrome</keyword>
	<keyword>Diamond Blackfan Anemia</keyword>
	<keyword>Dyskeratosis Congenita</keyword>
	<keyword>Fanconi Anemia</keyword>
	<keyword>Sickle Cell Disease</keyword>
	<keyword>Thalassemia</keyword>
	<keyword>Mucopolysaccharidosis</keyword>
	<keyword>Sphingolipidoses</keyword>
</DOC>